CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,830 | -19.8% | 40,000 | 0.0% | 0.00% | -20.0% |
| Q2 2023 | $2,281 | +158.3% | 40,000 | +100.0% | 0.01% | +150.0% |
| Q1 2023 | $883 | +5.0% | 20,000 | -4.0% | 0.00% | 0.0% |
| Q4 2022 | $841 | -99.9% | 20,843 | +4.2% | 0.00% | -50.0% |
| Q3 2022 | $1,304,000 | -54.7% | 20,000 | -56.2% | 0.00% | -50.0% |
| Q2 2022 | $2,877,000 | -1.7% | 45,660 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $2,926,000 | +8.4% | 45,660 | +29.9% | 0.01% | 0.0% |
| Q4 2021 | $2,699,000 | -51.8% | 35,160 | -30.8% | 0.01% | -56.2% |
| Q3 2021 | $5,599,000 | -17.0% | 50,810 | +13.4% | 0.02% | -20.0% |
| Q2 2021 | $6,744,000 | +61.2% | 44,810 | +23.4% | 0.02% | +42.9% |
| Q1 2021 | $4,183,000 | +62.5% | 36,310 | +122.6% | 0.01% | +40.0% |
| Q4 2020 | $2,574,000 | +125.2% | 16,310 | +21.3% | 0.01% | +100.0% |
| Q3 2020 | $1,143,000 | – | 13,450 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |